Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
Biosergen AS (BIOSGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.954x
Based on the latest financial reports, Biosergen AS (BIOSGN) has a cash flow conversion efficiency ratio of -0.954x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.75 Million) by net assets (Skr8.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biosergen AS - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Biosergen AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biosergen AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biosergen AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zenith Exports Limited
NSE:ZENITHEXPO
|
-0.036x |
|
Charn Issara Development Public Company Limited
BK:CI
|
0.112x |
|
Callan JMB Inc. Common Stock
NASDAQ:CJMB
|
-0.422x |
|
CIENA - Dusseldorf Stock Exchang
DU:CIE1
|
-0.055x |
|
Computer Direct
TA:CMDR
|
0.094x |
|
City Office
NYSE:CIO
|
0.022x |
|
CREDICORP (D8V.SG)
STU:D8V
|
0.098x |
|
NOVA MEASURING INTR
BE:NMR
|
0.052x |
Annual Cash Flow Conversion Efficiency for Biosergen AS (2019–2025)
The table below shows the annual cash flow conversion efficiency of Biosergen AS from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr8.12 Million | Skr-35.53 Million | -4.378x | -1193.49% |
| 2024-12-31 | Skr49.14 Million | Skr-16.63 Million | -0.338x | +97.80% |
| 2023-12-31 | Skr2.12 Million | Skr-32.60 Million | -15.408x | -1092.92% |
| 2022-12-31 | Skr22.79 Million | Skr-29.44 Million | -1.292x | +30.77% |
| 2021-12-31 | Skr20.23 Million | Skr-37.75 Million | -1.866x | -544.61% |
| 2020-12-31 | Skr-10.92 Million | Skr-4.58 Million | 0.420x | -14.94% |
| 2019-12-31 | Skr-4.69 Million | Skr-2.31 Million | 0.493x | -- |